Every Form 4 that GALERA THERAPEUTICS INC (GRTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GRTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GRTX filings page.
Galera Therapeutics, Inc. President and CEO Mel Sorensen reported issuer dispositions on August 3, 2026 in connection with the Galera and Obsidian mergers. A stock option covering 30,000 Galera shares at an exercise price of $4.40 per share and 975 Galera common shares were disposed to Galera and converted into Parent common stock at a 0.7019-for-1 exchange ratio. The reported Galera option and share positions were reduced to zero, and all figures reflect a 1-for-200 reverse stock split completed on July 12, 2026.
Galera Therapeutics, Inc. director Kevin G. Lokay reported the disposition to the issuer of 240 stock options (rights to buy Galera common stock at an exercise price of 8.2000 per share) on August 3, 2026, in connection with Galera’s merger into a wholly owned subsidiary of Gazelle Parent, Inc.
Footnotes explain that, at the Galera merger effective time, in-the-money options were fully vested and converted into Gazelle Parent common stock using a 0.7019 Galera exchange ratio, while certain non‑in‑the‑money options were cancelled for no consideration, and that figures reflect a 1-for-200 reverse stock split completed July 12, 2026.
Galera Therapeutics director and 10% owner Nancy T. Chang reported equity restructuring transactions tied to preferred stock and a merger. On May 15, 2026, 661.309 shares of Series B Preferred Stock were mandatorily converted into 661,309 shares of common stock. After a 1-for-200 reverse stock split and the August 3, 2026 Galera merger, 47,434 common shares and a stock option over 480 shares were disposed to Galera in connection with their conversion into Parent common stock using a 0.7019 Galera Exchange Ratio and a net-exercise formula for in-the-money options.
Galera Therapeutics director Lawrence M. Alleva reported issuer-related dispositions of his remaining Galera securities tied to the completion of Galera’s mergers with Obsidian Therapeutics and Gazelle Parent, Inc. On August 3, 2026, he disposed of 240 Galera stock options (exercise price $8.20, expiring February 23, 2035) and the reported directly held and trust-held Galera common shares, which were transferred to the issuer and converted under the merger terms. Each Galera common share became the right to receive 0.7019 shares of Parent common stock, and Galera stock options with exercise prices below $15.62 were fully vested and converted into Parent shares, while higher-priced options were cancelled for no consideration. All reported figures reflect a 1-for-200 reverse stock split completed on July 12, 2026.
Galera Therapeutics, Inc. reports that Chief Accounting Officer Joel F. Sussman disposed of a stock option covering 10,000 shares of common stock at a $4.40 exercise price, leaving no Galera options reported as outstanding. The option figures were adjusted for Galera’s 1-for-200 reverse stock split and the transaction occurred in connection with the August 3, 2026 mergers, under which each Galera share became exchangeable for 0.7019 shares of Parent common stock and in‑the‑money options (exercise price below $15.62) were fully vested and settled in Parent stock, while out‑of‑the‑money options were cancelled without consideration.
Galera Therapeutics, Inc. director Michael R. Friedman reported restructuring-related equity changes tied to a preferred conversion and subsequent merger. On May 15, 2026, 2,989.399 shares of Series B Non-Voting Convertible Preferred Stock held indirectly through an Equity Trust Company Roth IRA were mandatorily converted into 2,989,399 shares of Galera common stock at a 1,000:1 Conversion Ratio. On August 3, 2026, following a 1-for-200 reverse stock split and completion of the Galera merger into a parent entity, 41,631 indirectly held Galera common shares and 480 in-the-money stock options with an $8.20 exercise price were disposed to the issuer and converted into rights to receive Parent common stock under the merger exchange formulas.
Galera Therapeutics, Inc. reported a major ownership change as a key holder converted preferred stock into common shares. On May 15, 2026, Emerald Bioventures, LLC converted 20,813.8186 shares of Galera’s Series B Non-Voting Convertible Preferred Stock into 20,813,818 shares of common stock, based on a 1,000:1 Conversion Ratio.
After this derivative conversion, Emerald directly held 61,029,978 shares of Galera common stock. No fractional common shares were issued; instead, Galera will pay Emerald cash equal to the trading value of the fractional share amount on the conversion date. The filing is made jointly by Emerald and Timothy Opler, who is the managing member of Emerald and may be deemed to beneficially own the securities held by Emerald.
Galera Therapeutics director-associated IRA converted preferred stock into common shares through a company-initiated action. On April 7, 2026, 5,336.87 shares of Series B Non-Voting Convertible Preferred Stock indirectly held for Michael Friedman were mandatorily converted into 5,336,870 shares of Common Stock based on a 1,000:1 Conversion Ratio. The securities are held by Equity Trust Company, Custodian FBO Michael Friedman Roth IRA, which now holds 5,336,870 common shares indirectly following the conversion.
Galera Therapeutics director and 10% owner Nancy T. Chang converted preferred stock into common shares. On a board-initiated partial mandatory conversion effective April 7, 2026, 1,180.611 shares of Series B Non-Voting Convertible Preferred Stock were converted into 1,180,611 shares of common stock at a stated conversion price of $0.00 per share.
After the conversion, Chang directly held 8,825,543 shares of common stock and 661.309 shares of Series B Preferred Stock. This was a derivative conversion, not an open-market purchase or sale, and followed a February 12, 2026 amendment allowing the board to elect mandatory conversions based on a 1,000-to-1 conversion ratio.
Galera Therapeutics, Inc. (GRTX) president and CEO J. Mel Sorensen, who is also a director, reported an open market sale of company stock. On 11/20/2025, he sold 70,000 shares of common stock at a weighted average price of $0.0201 per share, with individual trades executed between $0.02 and $0.0201. After this transaction, he beneficially owned 195,029 shares of Galera Therapeutics common stock in direct ownership.